Gilead scores new FDA approval for drug obtained in billion-dollar purchase

Gilead Sciences has got a green light from the US Food and Drug Administration to use the drug Trodelvy for treating metastatic urothelial cancer. This is the second approval in a short time, as Trodelvy was recently approved for treating breast cancer.

Photo: v

US company Gilead Sciences is still profiting off the fact that it purchased biotech company Immunomedics for USD 21bn last year, and through this deal, it acquired the drug Trodelvy.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs